Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report.
Prior to therapy, model for end stage liver disease (MELD) scoring, diagnostic imaging and tumor staging were performed in a patient with T3 HCC. The patient received an orthotopic liver transplant (OLT) 42 days after treatment. The explant specimen showed complete necrosis of the target tumor. Follow-up of this patient has demonstrated no evidence of recurrence. There was no life threatening or fatal adverse experiences related to treatment. This case report documents the natural course, history and outcome of a patient treated with yttrium-90 for unresectable HCC. The patient was downstaged from T3 to T2 and was subsequently transplanted.
Kulik
Laura M
LM
Department of Hepatology, Robert H. Lurie Comprehensive Cancer Center, Northwestern Memorial Hospital, Chicago, IL 60611, USA.
Mulcahy
Mary F
MF
Hunter
Russell D
RD
Nemcek
Albert A
AA
Abecassis
Michael M
MM
Salem
Riad
R
D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D006498:Hepatectomy; D006801:Humans; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D008863:Microspheres; D009367:Neoplasm Staging; D015021:Yttrium Radioisotopes / Q000008:administration & dosage*
D015021:Yttrium Radioisotopes